




Coagulação e transfusão no peri-operatório


DR. ALEXANDRE TERUYA

- 
- Riscos transfusionais
 - Transplante hepático
 - Coagulação
 - Exames laboratoriais
 - Condutas
 - Drogas pró coagulantes

Reações Transfusionais

- | | |
|---------------------------------------|---------------|
| • Morrer atingido por meteorito | 1/100 bilhões |
| • Ser atingido por avião em terra | 1/25 milhões |
| • Morrer em acidente de avião | 1/4,2 milhões |
| • Contaminação HCV/HIV p/ transf | 1/1,5 milhão |
| • Ser atingido por um raio | 1/919.000 |
| • Morrer praticando canoagem | 1/100.000 |
| • Morrer pelo uso de anticoncepcional | 1/50.000 |
| • Morrer jogando futebol | 1/25.000 |
| • Receber transfusão incompatível | 1/25.000 |
| • Morrer de leucemia | 1/12.000 |
| • Morrer por complicações da gravidez | 1/4.200 |
| • Bater o carro (São Paulo) | 1/710 |
| • Casamento acabar em divórcio | 1/2,5 |


Reações Transfusionais



J Trauma. 2006;60:S46–S50.

Risks of Fresh Frozen Plasma and Platelets

Sheila MacLennan, MBBS, FRCP, FRCPath and Lorna M. Williamson, BSc, MD, FRCP, FRCPath



Original Research

CRITICAL CARE MEDICINE

TRALI

TACO

ALI

**Bacterial
contamination**


Sepsis

(*CHEST* 2007; 131:1308–1314)

**Fresh-Frozen Plasma and Platelet
Transfusions Are Associated With
Development of Acute Lung Injury in
Critically Ill Medical Patients***

Hasrat Khan, MD; Jon Belsher, MD; Murat Yilmaz, MD;
Bekele Afessa, MD, FCCP; Jeffrey L. Winters, MD; S. Breannan Moore, MD;
Rolf D. Hubmayr, MD, FCCP; and Ognjen Gajic, MD, FCCP

Transplante Hepático




Casuística Hepato

- Total - 180
- 2006 - 42
- 2007 - 60
- 2008 - 78

Fatores coagulantes sintetizados pelo fígado

- Fatores pró-coagulantes
 - Fatores II, VII, IX, X (dependentes de vitamina K)
 - Fatores V, VIII, XI, fibrinogênio
 - (Fatores VIII e vWF também são sintetizados extra-hepaticamente)
- Fatores anticoagulantes
 - Antitrombina, proteína C, proteína S

PULMONARY EMBOLISM IN DONORS UNDERGOING RIGHT LOBE HEPATECTOMY FOR LIVING DONOR TRANSPLANTATION



Teruya, A. *ASA Annual Meeting Abstracts* 2006

Terapia transfusional

- 13 transplantes – **32** ui CH

Dzik, WH. *Arch Surg* 1985;120(8)


- 636 transplantes – **19** ui CH

Lewis, JH. *Transfusion* 1987;27(3)

- 37 transplantes – **24,5** ui CH

Farrar, RP. *Transfusion* 1988;28(5)

Perioperative care of liver transplant patients in Brazil




Takaoka, F. *Intern Anesthesiol Clin* 2006; 44(4): 111-119


Redução na transfusão de hemocomponentes. Benefícios clínicos

- ↓ morbi-mortalidade (infecção, TRALI, hipervolemia)
- ↓ índice de rejeição
- ↓ tempo de ventilação mecânica
- ↓ permanência na UTI
- ↓ tempo de internação


Total Blood Transfusion and Mortality after Orthotopic Liver Transplantation




Sobrevida relacionada à transfusão de concentrados hemácias



The Impact of Intraoperative Transfusion of Platelets and Red Blood Cells on Survival After Liver Transplantation




Diminuição da utilização de hemocomponentes

- Indicação precoce do TOF
 - Preservação do enxerto
 - Técnica cirúrgica
-
- Técnica anestésica (hipotermia, acidose, cálcio)
 - Hematologia
- Cell saver
Drogas antifibrinolíticas
Drogas pró coagulantes
- 


Teruya, A. *Liver transplant* 2004; 10(6): 146

Ozier, Y. *Curr Opin Organ Transplant* 2008; 13: 304

Temperatura



Cascata da coagulação




David EW. *Science* 1964; 145:1310–1312

Rott, H. *Curr Opin Anaesthesiol* 2004; 17:159–163


Modelo celular da coagulação

- Iniciação – fator tecidual (fibroblastos, macrófagos, endotélio) e FVIIa
- Amplificação – plaquetas e fatores da coagulação
- Propagação – explosão de trombina


Iniciação



Amplificação e Propagação




Coagulation Defects Do Not Predict Blood Product Requirements During Liver Transplantation



Tromboelastógrafa



Fibrinólise



Tratamento

Practice Guidelines for Perioperative Blood Transfusion and Adjuvant Therapies

Nuttall, GA. *Anesthesiol* 2006; 105:198–208

	n	Percent Responding to Each Item				
		Strongly Agree	Agree	Uncertain	Disagree	Strongly Disagree
3. Intraoperative and postoperative management						
assess the presence of excessive microvascular bleeding				42.3	3.8	0.0
Periodically communicate with the surgical team to assess the presence of excessive microvascular bleeding	26	50.0*	38.5	7.7	3.8	0.0
Continuous monitoring for inadequate perfusion and oxygenation	26	57.7*	38.5	3.8	0.0	0.0
Usually administer red blood cells when the hemoglobin level is less than 6 g/dl	26	61.5*	30.8	3.8	3.8	0.0
Red blood cells are usually unnecessary when the hemoglobin level is greater than 10 g/dl	26	61.5*	34.6	3.8	0.0	0.0
Use normovolemic hemodilution or acute normovolemic hemodilution to reduce transfusion requirements when autologous blood is required or preferred	26	15.4	38.5*	30.8	11.5	3.8
<u>In a bleeding patient, administer platelets when the platelet count is less than 50,000 cells/mm³</u>	26	42.3	34.6*	7.7	15.4	0.0
<u>In a bleeding patient, administer FFP when INR (PT) or aPTT is elevated</u>	26	11.5	69.2*	0.0	19.2	0.0
<u>In a bleeding patient, administer cryoprecipitate when fibrinogen concentrations are < 80 mg/dl</u>	26	26.9	65.4*	3.8	3.8	0.0
When excessive microvascular bleeding (coagulopathy) occurs, administer:						
Desmopressin (DDAVP)	25	4.0	36.0	40.0*	16.0	4.0
Fibrin glue	25	20.0	40.0*	28.0	12.0	0.0
Thrombin gel	23	17.4	34.8*	34.8	13.0	0.0
Recombinant activated factor VII is an appropriate rescue drug when traditional, well-tested options have been exhausted	26	23.1	42.3*	34.6	0.0	0.0
To monitor for transfusion reactions:						
Periodically check for signs and symptoms	26	69.2*	30.8	0.0	0.0	0.0
Assess urine output and color	26	42.3	46.2*	7.7	3.8	0.0
Assess peak airway pressure	26	30.8	38.5*	26.9	3.8	0.0

Caso 1

- Extubação em SO
- 1 dia na UTI
- Sem transfusão de hemocomponentes na internação

Caso 1


- Masc , 46a, hemocromatose
- Trombose Veia Porta
- Tx fígado, Doador falecido

	Pré-op	Intra-op	UTI	PO1	PO2	PO3
TP%	37	32	26	45	62	
Fibrinogenio	78	77				
Plaquetas	21mil		31mil	22mil	17mil	19mil
Hb	14,6	13,4	14,1	11,6	10,5	10,3
Ht	40,3	41,2	39,3	32,3	29,5	28,8

Caso 2

- Masculino, 61 anos
- Cirrose alcoólica, Child C, Meld 16
- Encefalopatia grau II recente, ascite volumosa.
- Exames pré-op:
Hb 10,3; Ht 29; INR 1,2; Fibrinogênio 184;
Plaquetas 41.000; Uréia 46; Creatinina 0,7;
Transfusão intra-op: **CH 1, PFC 0, Plaq 0**
- Extubação na SO.
- Alta no 20º PO sem outras intercorrências
- TEG no início da cirurgia

Caso 2



Caso 3

- Masculino, 43 anos
- Cirrose alcoólica, Child B, Meld 11
- Sem cirurgia abdominal prévia
- Encefalopatia hepática, HDA
- Veia porta pérvia
- Pré operatório: Hb 13,4; HT 39,1%; INR 1,32; **Plaquetas 23.000**; Uréia 30; Creatinina 0,9; Na 139; K 4,1; BT 1,6

Caso 3

- CH 2 unidades
- PFC 0 unidades
- Crio 0 unidades
- Plaquetas 0 unidades

Preoperative Characteristics and Intraoperative Transfusion and Vasopressor Requirements in Patients With Low Vs. High MELD Scores

- Universidade Califórnia
- 01 jan- 31 dez de 2004
- 124 pacientes adultos, prospectivo
- Grupo 1: MELD \leq 30 (73 pacientes)
- Grupo 2: MELD $>$ 30 (51 pacientes)
- Transfusão de hemocomponentes

Preoperative Characteristics and Intraoperative Transfusion and Vasopressor Requirements in Patients With Low Vs. High MELD Scores

TABLE 2. Requirements of Transfusion in Different Periods During Liver Transplant Surgery (Units)

	Low MELD group (n = 73)	High MELD group (n = 51)	P values
RBC			
Prereperfusion	6.85 ± 5.94	9.85 ± 6.21	0.009
Postreperfusion	3.55 ± 3.55	5.83 ± 6.19	0.012
Total	10.62 ± 8.13	15.86 ± 9.56	0.001
Platelets			
Prereperfusion	0.23 ± 0.49	0.52 ± 0.55	0.004
Postreperfusion	0.61 ± 0.65	0.76 ± 0.64	NS
Total	0.86 ± 0.90	1.33 ± 0.89	0.004
Cryoprecipitate			
Prereperfusion	0.17 ± 0.41	0.41 ± 0.54	0.006
Postreperfusion	0.35 ± 0.51	0.59 ± 0.72	0.036
Total	0.52 ± 0.77	1.06 ± 0.95	0.001
Antifibrinolytics (n =)	40 (54.8)	39 (76.5)	0.014

NOTE: Data are presented as means ± SD or n (%).

Abbreviations: RBC, packed red blood cells; FFP, fresh frozen plasma; NS, not significant.

Preoperative Characteristics and Intraoperative Transfusion and Vasopressor Requirements in Patients With Low Vs. High MELD Scores

MELD

TABLE 4. Requirements of Total Transfusion in 5 Groups (Units)

	6-20	36-40					
scores	6-20	21-25	26-30	31-35	36-40	r_s	P values
Patients (n)	25	24	24	23	28		
RBC	10.6 ± 8.4	9.7 ± 6.4	11.5 ± 9.5	14.1 ± 7.5	17.3 ± 10.9	0.29	0.001
RBC	10.6 ± 8.4	9.7 ± 6.4	11.5 ± 9.5	14.1 ± 7.5	17.3 ± 10.9	0.29	0.001
Platelets	0.7 ± 0.7	1.0 ± 1.0	0.9 ± 0.9	1.3 ± 0.8	1.4 ± 1.0	0.26	0.004
Cryoprecipitate	0.6 ± 0.7	0.5 ± 0.7	0.5 ± 0.9	1.0 ± 0.8	1.1 ± 1.0	0.26	0.004

NOTE: Data are presented as mean ± SD.

Abbreviations: r_s , Spearman's rank correlation coefficient; RBC, packed red blood cells; FFP, fresh frozen plasma.

Pharmacokinetics of Beriplex in healthy volunteers

- Fatores pró coagulantes:
 - II, VII, IX e X
- Componentes antitrombóticos:
 - Proteína C e S, antitrombina III e heparina
- Derivado do plasma humano pasteurizado e nanofiltrado
- Reversão de anticoagulação

Caso 1- CCP

- MDA, 55a, fem, VHB e VHC, **Child C, O-**
- Ascite refratária, HDA, encefalopatia
- **Retransplante (disfunção primária)**
- Exames pré operatórios:
Hb= 10,4, Ht = 30,7, **INR=1,51, Plaquetas = 35000**
- **Beriplex (25ui/ kg)**
- Transfusão intraoperatória:
CH= 3u

Caso 2- CCP

- CBSF, 28a, fem, cirrose biliar, HCC, Child B, A+
- Ascite refratária, HDA, encefalopatia
- **Colecistectomia convencional**
- **Trombose Veia Porta**
- Exames pré operatórios:
Hb= 11,1, Ht = 31,7, **INR=1,59,**
Plaquetas = 35000
- **Beriplex (30ui/ kg)**
- Transfusão intraoperatória:
CH= 2u